Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Justin Cole

Nurse Practitioner, Gerontology Laurel, MS Nurse Practitioner

NPI 1588053052 CMS profile 10946177

1203 Jefferson St, Laurel, MS 39440

Open in the dashboard

General payments

$14,392

793 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Justin Cole of Laurel, MS is reported in the CMS Open Payments database as having received $14,392 across 793 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,772 125
2024 General $3,315 161
2023 General $2,938 166
2022 General $2,931 177
2021 General $2,437 164

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Justin Cole
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Justin Cole were reported at $2,772. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Justin Cole Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $2,437 $133 $44–$396 $132
2022 $2,931 $142 $48–$452 $149
2023 $2,938 $158 $53–$482 $160
2024 $3,315 $171 $55–$533 $164
2025 $2,772 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $986 75 payments
  2. Teva Pharmaceuticals USA, Inc. $867 39 payments
  3. ACADIA Pharmaceuticals Inc $780 50 payments
  4. SK Life Science, Inc. $776 43 payments
  5. UCB, Inc. $752 34 payments
  6. Novartis Pharmaceuticals Corporation $719 51 payments
  7. Pfizer Inc. $719 40 payments
  8. Biogen, Inc. $639 37 payments
  9. Argenx US, Inc. $507 24 payments
  10. Lilly USA, LLC $480 26 payments
  11. Other $7,167 374 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,210 789 payments
  2. Education $183 4 payments
Products named General payments · program years 2021–2025
  1. NUPLAZID $679 44 payments
  2. Briviact $606 27 payments
  3. Epidiolex $431 18 payments
  4. VYVGART Hytrulo $415 19 payments
  5. AIMOVIG $400 30 payments
  6. ZAVZPRET $389 21 payments
  7. NURTEC ODT $358 24 payments
  8. UBRELVY $357 35 payments
  9. PURIFIED CORTROPHIN GEL $343 16 payments
  10. KESIMPTA $343 26 payments
  11. Other $10,439 575 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 75 drugs

Part D claims

4,183

Median for Nurse Practitioner: 389

Drug cost

$911,471

Median for Nurse Practitioner: $21,885

Branded share of claims

27.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 23 $296,518
Rebif Rebidose Interferon Beta-1a/Albumin Brand 11 $115,578
Nuplazid Pimavanserin Tartrate Brand 23 $113,174
Vumerity Diroximel Fumarate Brand 11 $93,067
Eliquis Apixaban Brand 77 $59,328
Nurtec Odt Rimegepant Sulfate Brand 27 $49,416
Aimovig Autoinjector Erenumab-Aooe Brand 26 $31,430
Emgality Pen Galcanezumab-Gnlm Brand 20 $20,490
Aptiom Eslicarbazepine Acetate Brand 11 $18,838
Carbidopa-Levodopa Er Carbidopa/Levodopa Brand 125 $9,445

The 10 drugs with the highest cost, of 75 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$66,576

Medicare's payments for the services billed

Medicare patients

543

Average age 74

Services billed

1,655

310 women, 233 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 33%
Ischemic heart disease 33%
Depression 33%
Chronic kidney disease 20%
Alzheimer's or dementia 19%
Atrial fibrillation 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 50 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Epidiolex
$212 — —
NUPLAZID
$180 23 —
ZAVZPRET
$168 — —
PURIFIED CORTROPHIN GEL
$160 — —
FYCOMPA
$157 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 50 with Patron

Records

793 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Gerontology in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record